Private Placement (Form 8-K)

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 23, 2025, PAVmed Inc. (the "Company") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the Company's common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

The notification letter stated that the Company would be afforded 180 calendar days (until July 22, 2025) to regain compliance. In order to regain compliance, the closing bid price of the Company's common stock must be at least $1 for a minimum of ten consecutive business days. The notification letter also stated that, in the event the Company does not regain compliance within the initial 180-day period, the Company may be eligible for an additional 180-day period. If the Company is not eligible for the additional 180-day period, or if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, the Nasdaq Listing Qualifications Department will provide notice after the end of the initial 180-day period that the Company's securities will be subject to delisting.

The Nasdaq notification has no effect at this time on the listing of the Company's common stock or Series Z warrants, and the common stock and Series Z warrants will continue to trade uninterrupted under the symbol "PAVM" and "PAVMZ," respectively, or on the Company's efforts to regain compliance with Nasdaq Listing Rule 5550(b)(2), as discussed in its current report on Form 8-K filed, on January 21, 2025. The Company intends to consider all available options to regain compliance with the Nasdaq listing standards.